Deep vein thrombosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
* Study Start Date: March 2012 | * Study Start Date: March 2012 | ||
* Estimated Study Completion Date: December 2014 | * Estimated Study Completion Date: December 2014 | ||
* | * {| | ||
* |- | |||
* {|'''Arms''' | |||
Efficacy and Safety Study of Apixaban for Extended Treatment of [[Deep Vein Thrombosis]] or [[Pulmonary Embolism]]: Sponsored by Bristol-Myers Squibb and Pfizer <ref>http://clinicaltrials.gov/ct2/show/NCT00633893</ref> | Efficacy and Safety Study of Apixaban for Extended Treatment of [[Deep Vein Thrombosis]] or [[Pulmonary Embolism]]: Sponsored by Bristol-Myers Squibb and Pfizer <ref>http://clinicaltrials.gov/ct2/show/NCT00633893</ref> | ||
Revision as of 01:43, 20 June 2012
Ongoing Research
Phase 3 Trials
Acute Medically Ill venous thromboembolism (VTE) Prevention With Extended Duration Betrixaban Study (The APEX Study): Sponsored by Portola Pharmaceuticals
- Primary Outcome Measures: Composite of VTE (DVT and/or PE) and VTE death
- Secondary Outcome Measures: Number of patients with symptomatic VTE
- Estimated Enrollment: 6850
- Study Start Date: March 2012
- Estimated Study Completion Date: December 2014
- {|
- |-
- {|Arms
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism: Sponsored by Bristol-Myers Squibb and Pfizer [1]
- Primary Outcome Measures: Venous Thromboembolic Recurrence or Death
- Secondary Outcome Measures: Bleeding
- Estimated Enrollment: 2,430 patients
- Study Start Date: May 2008
- Estimated Study Completion Date: August 2012